Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gosogliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 14/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 14/20 | 1.00 |
| ▸ | FAP | Q12884 | 1/20 | 1.00 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gosogliptin SCHEMBL23715004 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3848283 | 0.93 | DPP4 (1.00) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3842688 | 0.90 | DPP4 (0.81) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL14648442 | 0.90 | DPP4 (0.81) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3849234 | 0.88 | DPP4 (0.79) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3842662 | 0.88 | DPP4 (0.78) | DPP4DPP8DPP7FAPDPP9 | |
| Hydrochloric Acid SCHEMBL3841149 | 0.87 | DPP4 (0.98) | DPP4DPP8DPP7FAPDPP9 | |
| Hydrochloric Acid SCHEMBL3841151 | 0.87 | DPP4 (0.98) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3840932 | 0.87 | DPP4 (0.77) | DPP4DPP8DPP7FAPDPP9 | |
| SCHEMBL3845134 | 0.86 | DPP4 (0.75) | DPP4DPP8DPP7FAPDPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 901 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | Universita' Degli Studi Di Roma “La Sapienza” (IT) | 2026-05-26 | — | — | US | claimed |
| EP-4735023-A2 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE | Piton Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| CN-121586585-A | Compounds for up-regulating myotrophic related protein levels in muscle cells and methods of use thereof | 肽智科技私人有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4694979-A2 | COMPOUNDS FOR UPREGULATING UTROPHIN LEVELS IN MUSCLE CELLS AND METHOD OF APPLICATION THEREOF | Peptris Technologies Private Limited (IN) | 2026-02-18 | — | — | EP | claimed |
| EP-4686474-A1 | DPP-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF AUTOIMMUNE LIVER DISEASES | Delta 4 GmbH (AT) | 2026-02-04 | — | — | EP | claimed |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | claimed |
| EP-4596044-A2 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS | Mankind Pharma Ltd. (IN) | 2025-08-06 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4554574-A2 | SMALL MOLECULE REGULATORS OF ALVEOLAR TYPE 2 CELL PROLIFERATION FOR THE TREATMENT OF PULMONARY DISEASES | The Scripps Research Institute (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2009147125-A1 | DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | WO | claimed |
| EP-1753748-B1 | PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PROD INC (US) | 2009-07-29 | — | — | EP | claimed |
| WO-2009022009-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| WO-2009022007-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | claimed |
| JP-4227660-B2 | — | — | 2009-02-18 | — | — | JP | claimed |
| JP-2007537231-A | — | — | 2007-12-20 | — | — | JP | claimed |
| US-7291618-B2 | Therapeutic compounds | PFIZER INC (US) | 2007-11-06 | — | — | US | claimed |
| EP-1753748-A1 | PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | Pfizer Products Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| WO-2005116014-A1 | PROLINE DERIVATIVES AND THEIR USE AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-12-08 | — | — | WO | claimed |
| US-20050256310-A1 | Therapeutic compounds | PFIZER INC | 2005-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256310-A1 | Therapeutic compounds | REN, SLC5A1, SLC5A2 | DPP4 26/4885DPP8 413/4885DPP7 274/4885 |
| US-20250312456-A1 | TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
| US-12636284-B2 | Compositions for use in the prevention and/or treatment of intellectual disability and neurodegenerative diseases in a subject with down syndrome | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 5/4885DPP7 3/4885 |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | GLP1R, DPP4, SLC5A2 | DPP4 2/4885DPP8 11/4885DPP7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.